Kolon Life Science signs technology transfer deal with Juniper Biologics
Kolon Life Science inked a technology transfer deal worth up to 723.4 billion won ($590 million) with Singapore's Juniper Biologics for its cell and gene therapy drug TG-C, otherwise known as Invossa.